# Natural Compounds Derived from Chilean Species and Their Cytotoxic Potential Against Cancer

**Authors:** Tania Koning, Gloria M. Calaf

PMC · DOI: 10.3390/cancers18040656 · Cancers · 2026-02-17

## TL;DR

This paper reviews twelve Chilean plant species with potential to fight cancer by inducing cell death and other anti-cancer effects.

## Contribution

The study compiles evidence on the cytotoxic potential of twelve under-researched Chilean plant species against cancer.

## Key findings

- Twelve Chilean species show cytotoxic effects like cell death and reduced viability in cancer cells.
- These plants operate through mechanisms such as apoptosis and mitochondrial alteration.
- The compounds display high specificity and low toxicity, suggesting therapeutic potential.

## Abstract

Medicinal plants have been used in therapy since ancient times and remain important in human health. Traditionally, they have been employed to treat various diseases, including cancer, a major global health challenge with profound social and economic implications, responsible for approximately 17% of worldwide mortality. Numerous studies have identified plant compounds and their mechanisms of action, supporting further clinical research into their therapeutic potential. Within this context, Chile has remarkable biodiversity, characterized by high endemism across varied environments and climates, presenting a valuable source of bioactive compounds that merits deeper exploration. This work gathers and analyzes evidence regarding the cytotoxic properties of twelve Chilean species. These species have demonstrated the capacity to induce cell death, reduce cellular viability, attenuate clonogenic growth, induce senescent phenotype, and even show anti-angiogenic effects. These species display low toxicity and high specificity, operating through mechanisms such as cell cycle arrest, apoptosis induction, chromatin fragmentation, and mitochondrial alteration.

Cancer remains a pressing global health concern with profound social and economic implications, accounting for nearly 17% of all deaths worldwide. Throughout history, medicinal plants have been employed in traditional healing practices to treat various illnesses, including cancer, and they continue to play a vital role in modern healthcare. Chile, a South American country with a diverse range of climates and landscapes, harbors exceptional biodiversity that offers many natural products with potential cytotoxic properties. This study presents a comprehensive review of the literature, collecting existing evidence that twelve Chilean species, Leptocarpha rivularis, Peumus boldus, Aristotelia chilensis, Drimys winteri, Solidago chilensis, Buddleja globosa, Senecio graveolens, Geoffroea decorticans, Ugni molinae, Austrocedrus chilensis, Gracilaria chilensis, and Kageneckia oblonga, exhibit potential cytotoxic properties against cancer. Extracts and isolated molecules from these species have been shown to induce cell death, reduce cellular viability, attenuate clonogenic growth, induce senescent phenotype, and even exert anti-angiogenic effects. These species display high toxicity and specificity, operating through mechanisms such as cell cycle arrest, induction of apoptosis, chromatin fragmentation, and mitochondrial alteration. The findings summarized here support the importance of further research. Many of the bioactive compounds identified remain poorly characterized, and their molecular mechanisms of action are not yet fully understood. By consolidating current evidence, this work establishes a foundation for future research aimed at developing therapeutic applications that harness Chilean natural products to prevent cancer progression.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)
- **Species:** Leptocarpha rivularis (taxon 3027750), Peumus boldus (taxon 63812), Aristotelia chilensis (taxon 138855), Drimys winteri (taxon 3419), Solidago chilensis (taxon 2707859), Buddleja globosa (taxon 168495), Geoffroea decorticans (taxon 107362), Ugni molinae (taxon 260145), Austrocedrus chilensis (taxon 103964), Kageneckia oblonga (taxon 133198)

## Full-text entities

- **Genes:** Casp3 (caspase 3) [NCBI Gene 12367] {aka A830040C14Rik, AC-3, CASP-3, CC3, CPP-32, CPP32}, HSPA4 (heat shock protein family A (Hsp70) member 4) [NCBI Gene 3308] {aka APG-2, HEL-S-5a, HS24/P52, HSPH2, RY, hsp70}, Bax (BCL2-associated X protein) [NCBI Gene 12028], IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, Pparg (peroxisome proliferator activated receptor gamma) [NCBI Gene 19016] {aka Nr1c3, PPAR-gamma, PPAR-gamma2, PPARgamma, PPARgamma2}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, Cat (catalase) [NCBI Gene 12359] {aka 2210418N07, Cas-1, Cas1, Cs-1}, FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353] {aka AP-1, C-FOS, p55}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, BCHE (butyrylcholinesterase) [NCBI Gene 590] {aka BCHED, CHE1, CHE2, E1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}, Mapk14 (mitogen-activated protein kinase 14) [NCBI Gene 26416] {aka CSBP2, Crk1, Csbp1, Mxi2, PRKM14, PRKM15}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}, CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, ctnnb1.L (catenin beta 1 L homeolog) [NCBI Gene 399274] {aka B-catenin, beta-catenin, ctnnb, ctnnb1, ctnnb1-a, ctnnb1-b}, CASP9 (caspase 9) [NCBI Gene 842] {aka APAF-3, APAF3, ICE-LAP6, MCH6, PPP1R56}, Trp53-ps (transformation related protein 53, pseudogene) [NCBI Gene 22060], NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, MAP1LC3A (microtubule associated protein 1 light chain 3 alpha) [NCBI Gene 84557] {aka ATG8E, LC3, LC3A, MAP1ALC3, MAP1BLC3}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, SOD2 (superoxide dismutase 2) [NCBI Gene 6648] {aka GC1, GClnc1, IPO-B, IPOB, MNSOD, MVCD6}, Bax (BCL2 associated X, apoptosis regulator) [NCBI Gene 24887], BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, CASP8 (caspase 8) [NCBI Gene 841] {aka ALPS2B, CAP4, Casp-8, FLICE, MACH, MCH5}, Mki67 (antigen identified by monoclonal antibody Ki 67) [NCBI Gene 17345] {aka D630048A14Rik, Ki-67, Ki67}, TERT (telomerase reverse transcriptase) [NCBI Gene 7015] {aka CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, Il4 (interleukin 4) [NCBI Gene 16189] {aka BSF-1, Il-4}, Bcl2 (B cell leukemia/lymphoma 2) [NCBI Gene 12043] {aka Bcl-2, C430015F12Rik, D630044D05Rik, D830018M01Rik}, Mapk1 (mitogen-activated protein kinase 1) [NCBI Gene 26413] {aka 9030612K14Rik, ERK, Erk2, MAPK2, PRKM2, Prkm1}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], NFKBIA (NFKB inhibitor alpha) [NCBI Gene 4792] {aka EDAID2, IKBA, MAD-3, NFKBI}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, Casp3 (caspase 3) [NCBI Gene 25402] {aka CPP32-beta, Lice, Yama}, Bcl2 (BCL2, apoptosis regulator) [NCBI Gene 24224] {aka Bcl-2}
- **Diseases:** cervical carcinoma (MESH:D002583), inflammation (MESH:D007249), injury to (MESH:D014947), syphilis (MESH:D013587), glioma (MESH:D005910), melanoma (MESH:D008545), colon, prostate, liver, and lung cancers (MESH:D011471), asthma (MESH:D001249), myeloma (MESH:D009101), lung carcinoma (MESH:D008175), cancer (MESH:D009369), cervical adenocarcinoma (MESH:D000230), altitude sickness (MESH:D000532), overweight (MESH:D050177), hepatic and kidney disorders (MESH:D058186), diarrhea (MESH:D003967), non-melanoma skin cancers (MESH:D012878), hypoxic (MESH:D002534), hemorrhagic (MESH:D006470), obesity (MESH:D009765), Gastric cancer (MESH:D013274), low back pain (MESH:D017116), squamous cell carcinoma (MESH:D002294), hypoxia (MESH:D000860), non (MESH:C580335), colon adenocarcinoma (MESH:D003110), renal (MESH:D006030), metabolic (MESH:D008659), fever (MESH:D005334), tendinitis (MESH:D052256), carcinogenic (MESH:D011230), sore throat (MESH:D010612), breast (MESH:D061325), deaths (MESH:D003643), endometrial adenocarcinoma (MESH:D016889), colon cancer (MESH:D015179), leukemia (MESH:D007938), metastasis (MESH:D009362), genitourinary malignancies (MESH:D014565), dysentery (MESH:D004403), Cytotoxic (MESH:D064420), digestive disorders (MESH:D004066), ulcer (MESH:D014456), bronchitis (MESH:D001991), infections (MESH:D007239), scabies (MESH:D012532), gallbladder, and gastrointestinal disorders (MESH:D005767), ovarian cancer (MESH:D010051), allergies (MESH:D004342), liver and gallbladder pain (MESH:D017093), gastric (MESH:D013272), breast cancer (MESH:D001943), bladder cancer (MESH:D001749), communicable (MESH:D003141), solid (MESH:D018250), colon, breast, prostate, (MESH:D011472), HCC (MESH:D006528), basal cell carcinoma (MESH:D002280), necrosis (MESH:D009336)
- **Chemicals:** Hex (MESH:C026385), acids (MESH:D000143), Gallic acid (MESH:D005707), benzo [a]pyrene (MESH:D001564), methanol (MESH:D000432), agar (MESH:D000362), esters (MESH:D004952), rutin (MESH:D012431), flavonols (MESH:D044948), ferruginol (MESH:C431074), podophyllotoxin (MESH:D011034), quercetin (MESH:D011794), DCM (MESH:D008752), vitamin E (MESH:D014810), paclitaxel (MESH:D017239), phenolic acids (MESH:C017616), myricetin (MESH:C040015), 23,24-dihydrocucurbitacin F (MESH:C575988), terpene (MESH:D013729), delphinidin-3-rutinoside (MESH:C010705), apigenin (MESH:D047310), Essential oils (MESH:D009822), Catechin (MESH:D002392), drimenol (MESH:C481244), phenol (MESH:D019800), water (MESH:D014867), kaempferol (MESH:C006552), alpha-pinene (MESH:C005451), delphinidin 3-sambubioside (MESH:C505011), NO (MESH:D009569), beta-pinene (MESH:C010789), EtOH (MESH:D000431), 4-hydroxy-3-(3-methyl-2-butenyl) acetophenone (MESH:C474241), flavonol (MESH:C041477), Yatein (MESH:C452802), Usnic acid (MESH:C073339), alkaloid (MESH:D000470), Vitamin C (MESH:D001205), gamma-tocopherol (MESH:D024504), retinoic acid (MESH:D014212), linalool (MESH:C018584), beta-caryophyllene (MESH:C024714), ethyl acetate (MESH:C007650), H2O2 (MESH:D006861), Cisplatin (MESH:D002945), EtOAc (-), O2 - (MESH:D013481), polygodial (MESH:C034380), pyrogallol (MESH:D011748), Tannins (MESH:D013634), triterpenoid (MESH:D014315), LTC (MESH:C093534), phenols (MESH:D010636), cucurbitacin (MESH:D054728), monoterpene (MESH:D039821), oils (MESH:D009821), prunasin (MESH:C019063), caryophyllene oxide (MESH:C515179), benzylisoquinoline (MESH:D044182), lignan (MESH:D017705)
- **Species:** Geoffroea decorticans (species) [taxon 107362], Solidago chilensis (species) [taxon 2707859], Drimys winteri var. winteri (varietas) [taxon 529610], Ugni molinae (species) [taxon 260145], Hibiscus sabdariffa (red-sorrel, species) [taxon 183260], Aristotelia chilensis (species) [taxon 138855], Mus musculus (house mouse, species) [taxon 10090], Peumus boldus (species) [taxon 63812], Kageneckia oblonga (species) [taxon 133198], Drimys winteri (species) [taxon 3419], Austrocedrus chilensis (species) [taxon 103964], Agarophyton chilense (species) [taxon 2510777], Homo sapiens (human, species) [taxon 9606], Trypanosoma brucei brucei (subspecies) [taxon 5702], Helicobacter pylori (species) [taxon 210], Rattus norvegicus (brown rat, species) [taxon 10116], Xenopus laevis (African clawed frog, species) [taxon 8355], PX clade (clade) [taxon 569578], Buddleja globosa (species) [taxon 168495], Apis mellifera (bee, species) [taxon 7460]
- **Cell lines:** T48 — Homo sapiens (Human), Gingival squamous cell carcinoma, Cancer cell line (CVCL_S692), HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), HL-60 — Homo sapiens (Human), Adult acute myeloid leukemia with maturation, Cancer cell line (CVCL_0002), P-388 — Mus musculus (Mouse), Mouse lymphoma, Cancer cell line (CVCL_7222), MKN-45 — Homo sapiens (Human), Gastric adenocarcinoma, Cancer cell line (CVCL_0434), A-549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), RAW-264.7 — Mus musculus (Mouse), Mouse leukemia, Cancer cell line (CVCL_0493), HCT 116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291), GES-1 — Homo sapiens (Human), Transformed cell line (CVCL_EQ22), 786-O — Homo sapiens (Human), Renal cell carcinoma, Cancer cell line (CVCL_1051), U138-MG — Homo sapiens (Human), Astrocytoma, Cancer cell line (CVCL_0020), ZR-75-1 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0588), ACHN — Homo sapiens (Human), Papillary renal cell carcinoma, Cancer cell line (CVCL_1067), H460 — Homo sapiens (Human), Lung large cell carcinoma, Cancer cell line (CVCL_0459), CCD841 — Homo sapiens (Human), Finite cell line (CVCL_2871), Ishikawa — Homo sapiens (Human), Type I endometrial adenocarcinoma, Cancer cell line (CVCL_2529), DU-145 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0105), P3X — Mus musculus (Mouse), Mouse multiple myeloma, Cancer cell line (CVCL_3411), C6 — Rattus norvegicus (Rat), Rat malignant glioma, Cancer cell line (CVCL_0194), AGS — Homo sapiens (Human), Gastric adenocarcinoma, Cancer cell line (CVCL_0139), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), NCI-H1975 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_1511), CaCo-2 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0025), T84 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0555), MDA MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062), MCF-10F — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_3633), HT-22 — Mus musculus (Mouse), Transformed cell line (CVCL_0321), Huh-7 — Homo sapiens (Human), Adult hepatocellular carcinoma, Cancer cell line (CVCL_0336), HaCaT — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0038), HEK-293 — Homo sapiens (Human), Transformed cell line (CVCL_0045), U87-MG — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_0022), Sarcoma 180 — Mus musculus (Mouse), Mouse fibrosarcoma, Cancer cell line (CVCL_3598), SKHep-1 — Homo sapiens (Human), Liver and intrahepatic bile duct epithelial neoplasm, Cancer cell line (CVCL_0525), A375 — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_0132), LNCaP — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0395), C6 glioma — Rattus norvegicus (Rat), Rat malignant glioma, Cancer cell line (CVCL_3581), fibroblasts — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594), PC-3 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0035), SCC-4 — Homo sapiens (Human), Tongue squamous cell carcinoma, Cancer cell line (CVCL_1684), CoN — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_RL17), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), M14 — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_1395), SKOV3 — Homo sapiens (Human), Ovarian serous cystadenocarcinoma, Cancer cell line (CVCL_0532), HTR-8/SVneo — Homo sapiens (Human), Transformed cell line (CVCL_7162), T24 — Homo sapiens (Human), Bladder carcinoma, Cancer cell line (CVCL_0554), HT-29 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0320), GRX — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_M115)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12939060/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939060/full.md

## References

188 references — full list in the complete paper: https://tomesphere.com/paper/PMC12939060/full.md

---
Source: https://tomesphere.com/paper/PMC12939060